• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mink Therapeutics Inc (NQ: INKT )

    0.9220 +0.0120 (+1.32%)
    Streaming Delayed Price Updated: 3:13 PM EDT, Jul 25, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 82,041
    Open 1.000
    Bid (Size) 0.9220 (1)
    Ask (Size) 0.9490 (2)
    Prev. Close 0.9100
    Today's Range 0.9200 - 1.000
    52wk Range 0.7500 - 1.960
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
    From MiNK Therapeutics
    Via GlobeNewswire
    MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
    From MiNK Therapeutics
    Via GlobeNewswire

    Performance

    YTD
    -15.41%
    -15.41%
    1 Month
    +2.44%
    +2.44%
    3 Month
    +3.71%
    +3.71%
    6 Month
    +2.78%
    +2.78%
    1 Year
    -45.76%
    -45.76%

    More News

    Read More
    INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q1 2024
    Via InvestorPlace
    MiNK Reports First Quarter 2024 Results
    From MiNK Therapeutics
    Via GlobeNewswire
    Earnings Outlook For MiNK Therapeutics
    Via Benzinga
    Why MiNK Therapeutics Stock Is Up 11% Monday
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
    From MiNK Therapeutics
    Via GlobeNewswire
    MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
    From MiNK Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
    From MiNK Therapeutics
    Via GlobeNewswire
    Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    INKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023
    Via InvestorPlace
    MiNK Reports Fourth Quarter and Year-End 2023 Results
    From MiNK Therapeutics
    Via GlobeNewswire
    MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
    From MiNK Therapeutics
    Via GlobeNewswire
    Earnings Scheduled For March 21, 2024
    Via Benzinga
    MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
    From MiNK Therapeutics
    Via GlobeNewswire
    First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
    From MiNK Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
    From MiNK Therapeutics
    Via GlobeNewswire
    MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
    From MiNK Therapeutics
    Via GlobeNewswire
    ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
    From MiNK Therapeutics
    Via GlobeNewswire
    MiNK Therapeutics Reports Third Quarter 2023 Results
    From MiNK Therapeutics
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.